PRMT5 and CDK4/6 inhibition result in distinctive patterns of alternative splicing

To investigate the full effects of inhibition of CDK4/6 on splicing events in melanoma and the extent to which they are dependent on PRMT5 . We performed full-length mRNA sequencing on CHL1 and A375 melanoma cell lines treated with the CDK4/6 inhibitor palbociclib and the PRMT5 inhibitor GSK3326595 and CTX085 and analysed data for differential gene expression and differential pre-mRNA splicing induced by these agents. Comparative gene expression profiling analysis of RNA-seq data for CDK4/6 and PRMT5 inhibited CHL1 and A375 melanoma cells.